Literature DB >> 16030196

Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia.

Rongzhen Xu1, Yingzi Yu, Shu Zheng, Xiaoying Zhao, Qinghua Dong, Zhiwen He, Yun Liang, Qinghua Lu, Yongmin Fang, Xiaoxian Gan, Xiaohua Xu, Suzhan Zhang, Qi Dong, Xiaohong Zhang, Gen-Sheng Feng.   

Abstract

Shp2 tyrosine phosphatase plays a critical role in hematopoiesis, and dominant active mutations have been detected in the human gene PTPN11, encoding Shp2, in child leukemia patients. We report here that although no such mutations were detected in 44 adult leukemia patients screened, Shp2 expression levels were significantly elevated in primary leukemia cells and leukemia cell lines, as compared with normal hematopoietic progenitor cells. The Shp2 protein amounts correlated well with the hyperproliferative capacity but were inversely associated with the differentiation degree of leukemia cells. Suppression of Shp2 expression induced apoptosis and inhibition of leukemic cell clonogenic growth. Notably, the majority of Shp2 was preferentially localized to the plasma membrane and was constitutively phosphorylated on tyrosine in leukemia cells, and also in normal hematopoietic cells following mitogenic stimulation. Based on these results, we propose that aberrantly increased expression of Shp2 may contribute, collaboratively with other factors, to leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16030196      PMCID: PMC1895328          DOI: 10.1182/blood-2004-10-4057

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt.

Authors:  Y Hakak; Y S Hsu; G S Martin
Journal:  Oncogene       Date:  2000-06-29       Impact factor: 9.867

Review 2.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

3.  The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression.

Authors:  A Cappellini; G Tabellini; M Zweyer; R Bortul; P L Tazzari; A M Billi; F Falà; L Cocco; A M Martelli
Journal:  Leukemia       Date:  2003-11       Impact factor: 11.528

4.  The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.

Authors:  C J Wu; D M O'Rourke; G S Feng; G R Johnson; Q Wang; M I Greene
Journal:  Oncogene       Date:  2001-09-20       Impact factor: 9.867

5.  Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.

Authors:  Suzanne Schubbert; Kenneth Lieuw; Sara L Rowe; Connie M Lee; Xiaxin Li; Mignon L Loh; D Wade Clapp; Kevin M Shannon
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

6.  A definitive role of Shp-2 tyrosine phosphatase in mediating embryonic stem cell differentiation and hematopoiesis.

Authors:  Rebecca J Chan; Scott A Johnson; Yanjun Li; Mervin C Yoder; Gen-Sheng Feng
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

7.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

8.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

Authors:  M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

9.  Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling.

Authors:  Wen-Mei Yu; Teresa S Hawley; Robert G Hawley; Cheng-Kui Qu
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

10.  Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.

Authors:  Mignon L Loh; Shashaank Vattikuti; Suzanne Schubbert; Melissa G Reynolds; Elaine Carlson; Kenneth H Lieuw; Jennifer W Cheng; Connie M Lee; David Stokoe; Jeannette M Bonifas; Nicole P Curtiss; Jason Gotlib; Soheil Meshinchi; Michelle M Le Beau; Peter D Emanuel; Kevin M Shannon
Journal:  Blood       Date:  2003-11-26       Impact factor: 22.113

View more
  48 in total

1.  A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation.

Authors:  Hui Huang; Andrew J Woo; Zachary Waldon; Yocheved Schindler; Tyler B Moran; Helen H Zhu; Gen-Sheng Feng; Hanno Steen; Alan B Cantor
Journal:  Genes Dev       Date:  2012-07-03       Impact factor: 11.361

2.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 3.  Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer.

Authors:  Lakshmi Reddy Bollu; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Clin Cancer Res       Date:  2017-01-13       Impact factor: 12.531

Review 4.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

Review 5.  Role of protein tyrosine phosphatases in cancer.

Authors:  Tasneem Motiwala; Samson T Jacob
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2006

6.  Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.

Authors:  Klaus Hellmuth; Stefanie Grosskopf; Ching Tung Lum; Martin Würtele; Nadine Röder; Jens Peter von Kries; Marta Rosario; Jörg Rademann; Walter Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-14       Impact factor: 11.205

7.  A critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells.

Authors:  Liang Li; Hardik Modi; Tinisha McDonald; John Rossi; Jiing-Kuan Yee; Ravi Bhatia
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

8.  Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis.

Authors:  Emilie A Bard-Chapeau; Shuangwei Li; Jin Ding; Sharon S Zhang; Helen H Zhu; Frederic Princen; Diane D Fang; Tao Han; Beatrice Bailly-Maitre; Valeria Poli; Nissi M Varki; Hongyang Wang; Gen-Sheng Feng
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

9.  The phosphatase Shp2 is required for signaling by the Kaposi's sarcoma-associated herpesvirus viral GPCR in primary endothelial cells.

Authors:  Thomas Bakken; Meilan He; Mark L Cannon
Journal:  Virology       Date:  2009-12-09       Impact factor: 3.616

10.  Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome.

Authors:  John M Graham; Nancy Kramer; Bassem A Bejjani; Christian T Thiel; Claudio Carta; Giovanni Neri; Marco Tartaglia; Martin Zenker
Journal:  Am J Med Genet A       Date:  2009-10       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.